The life insurance industry continues to closely monitor advances in aging science, particularly the development of biological aging clocks, as researchers explore their potential to improve mortality risk assessment and underwriting decisions.

Unlike many sectors outside the life sciences, life insurers have long recognized the potential impact of therapies designed to treat aging as a medical condition. With substantial investments in medical research analysis and long-term forecasting, insurers view healthy lifespan extension as both a significant opportunity and a potential challenge to existing business models. Accurate forecasting of longevity trends is expected to play an increasingly important role in the industry’s future.

A recent analysis examines the growing interest in biological aging clocks, tools that estimate an individual’s biological age by analyzing biomarkers such as DNA methylation patterns. These technologies are designed to predict mortality risk across populations and have generated interest as a possible complement to traditional health assessments.

The report presents a hypothetical case of a healthy 50-year-old insurance applicant whose biological age is estimated at 46 by a commercial longevity test, suggesting a slower-than-average rate of aging and a potentially longer life expectancy. While such results may appear promising, researchers caution that current biological age measurements should not yet be considered definitive indicators of an individual’s mortality risk.

Chronological age has served as the foundation of life insurance mortality assessment for centuries because of its consistency and proven relationship with mortality. However, it does not account for individual differences in health status. Biological age aims to address this gap by reflecting the body’s functional condition and the cumulative molecular and cellular changes associated with aging. In theory, this could allow insurers to distinguish between individuals of the same chronological age who have markedly different health profiles.

Most commercially available biological age assessments rely on epigenetic clocks, which estimate age by analyzing DNA methylation patterns at selected genomic sites. These algorithms are trained using large population datasets to minimize prediction errors across groups rather than to provide highly accurate assessments for individual users.

According to the analysis, this population-based design presents important limitations for insurance underwriting. Epigenetic clocks can produce biologically variable results when applied to individuals and may be less accurate when used outside the populations on which they were originally trained, such as exceptionally healthy individuals or self-selected consumers who purchase commercial longevity tests.

Researchers also note that epigenetic age should not be interpreted in the same manner as established clinical biomarkers such as body mass index, blood glucose levels, or blood pressure, all of which have well-established value in assessing individual health risks.

At present, evidence suggests that biological aging clocks do not outperform conventional mortality predictors, including chronological age, sex, smoking history, blood pressure, body mass index, and medical history, in estimating life insurance risk. While biological age measurements may eventually provide additional insights for certain groups, such as younger individuals with few traditional risk factors or older adults with otherwise favorable health profiles, further long-term studies are needed to establish their practical value.

The analysis concludes that although biological aging clocks remain a promising area of research, they are not yet ready to replace or significantly enhance current life insurance underwriting practices. Continued validation through longitudinal research will be necessary before these tools can be confidently applied to individual risk assessment.